- Clozapine N-Oxide
-
- $30.00 / 2mg
-
2026-03-04
- CAS:34233-69-7
- Min. Order:
- Purity: 99.74%
- Supply Ability: 10g
- Clozapine N-oxide
-
- $15.00 / 1KG
-
2021-07-13
- CAS:34233-69-7
- Min. Order: 1KG
- Purity: 99%+ HPLC
- Supply Ability: Monthly supply of 1 ton
- Clozapine N-oxide
-
- $15.00 / 1KG
-
2021-07-09
- CAS:34233-69-7
- Min. Order: 1KG
- Purity: 99%+ HPLC
- Supply Ability: Monthly supply of 1 ton
|
| | CLOZAPINE N-OXIDE Basic information |
| Product Name: | CLOZAPINE N-OXIDE | | Synonyms: | e)(1,4)diazepine,8-chloro-11-(4-methyl-1-piperazinyl)-5h-dibenzo(n-oxide;CLOZAPINE N-OXIDE;8-CHLORO-11-[4-METHYL-1-PIPERAZINYL]-5H-DIBENZO[B,E][1,4]DIAZEPINE N-OXIDE;MAJORMETABOLITEOFCLOZAPINE.POSSESSESLITTLEORNOACTIVITYAT5-HTRECEPTORS;Clozapine N-oxide Methanol Adduct;Clozapine N-oxide solution;Clozapine N-oxide (CNO);8-Chloro-11-(4-methyl-4-oxido-1-piperazinyl)-5H-dibenzo[b,e][1,4]diazepine | | CAS: | 34233-69-7 | | MF: | C18H19ClN4O | | MW: | 342.82 | | EINECS: | | | Product Categories: | Various Metabolites and Impurities;Metabolites | | Mol File: | 34233-69-7.mol |  |
| | CLOZAPINE N-OXIDE Chemical Properties |
| Melting point | 190-248°C | | Fp | 9℃ | | storage temp. | -20°C Freezer, Under Inert Atmosphere | | solubility | Soluble in DMSO. | | pka | 6.86±0.20(Predicted) | | form | powder | | color | Yellow | | biological source | synthetic | | Stability: | Stable for 1 year from date of purchase as supplied. Solutions in DMSO or ethanol may be stored at -20°C for up to 3 months. | | InChI | InChI=1S/C18H19ClN4O/c1-23(24)10-8-22(9-11-23)18-14-4-2-3-5-15(14)20-16-7-6-13(19)12-17(16)21-18/h2-7,12,20H,8-11H2,1H3 | | InChIKey | OGUCZBIQSYYWEF-UHFFFAOYSA-N | | SMILES | N1=C(N2CC[N+]([O-])(C)CC2)C2=CC=CC=C2NC2=CC=C(Cl)C=C12 |
| Hazard Codes | Xn,T,F | | Risk Statements | 22-36/37/38-39/23/24/25-23/24/25-11 | | Safety Statements | 26-36-45-36/37-16-7 | | RIDADR | UN 2811 6.1/PG 3 | | WGK Germany | 3 | | RTECS | HP1760000 | | HazardClass | 6.1(b) | | PackingGroup | III | | HS Code | 29335990 | | Storage Class | 6.1C - Combustible acute toxic Cat.3
toxic compounds or compounds which causing chronic effects | | Hazard Classifications | Acute Tox. 3 Oral
STOT SE 3 |
| | CLOZAPINE N-OXIDE Usage And Synthesis |
| Description | Clozapine-N-oxide (34233-69-7) is a clozapinemetabolite1which is pharmacologically inert2. Agonist at human muscarinic designer receptors known as DREADDs, (designer receptors exclusively activated by designer drug).2May be used to control grafted human pluripotent stem cell-derived neurons engineered to express DREADDs.3,4Numerous other applications.5,6 | | Chemical Properties | Yellow Solid | | Uses | Clozapine N-oxide has been used:
- for the activation of human M4 muscarinic (hM4Di) in primary motor cortex
- for inducing in vivo chemogenetic manipulation and impairing locomotor activity in Th-cre transgenic mice
- in behavioral testing in mice and for stimulating (HEK293) cells
| | Uses | A 5-HT2 antagonist. A major metabolite of clozapine that can be monitored by HPLC. Possesses little or no activity towards serotonin receptors | | Definition | ChEBI: Clozapine N-oxide is a dibenzodiazepine. | | General Description | Clozapine N-oxide (CNO), inactive from of clozapine drug, activates G-protein-coupled receptors (GPCRs). CNO serves as a synthetic ligand for engineered human muscarinic receptor. It elicits clozapine-like effects upon metabolic conversion. Clozapine conversion to CNO favors its passage through blood-brain barrier. | | Biochem/physiol Actions | 5-HT2 serotonin receptor antagonist; major metabolite of clopazine that can be monitored by HPLC. | | storage | Room temperature (desiccate) | | References | [1] BIRGIT EIERMANN. The involvement of CYP1A2 and CYP3A4 in the metabolism of clozapine[J]. British journal of clinical pharmacology, 2003, 44 5: 439-446. DOI:10.1046/j.1365-2125.1997.t01-1-00605.x
[2] BLAINE N ARMBRUSTER. Evolving the lock to fit the key to create a family of G protein-coupled receptors potently activated by an inert ligand.[J]. Proceedings of the National Academy of Sciences of the United States of America, 2007: 5163-5168. DOI:10.1073/pnas.0700293104
[3] YUEJUN CHEN. Chemical Control of Grafted Human PSC-Derived Neurons in a Mouse Model of Parkinson’s Disease.[J]. Cell stem cell, 2016, 18 6: 817-826. DOI:10.1016/j.stem.2016.03.014
[4] ELENA M VAZEY Gary A J. Designer receptors: therapeutic adjuncts to cell replacement therapy in Parkinson’s disease.[J]. Journal of Clinical Investigation, 2014, 124 7: 2858-2860. DOI:10.1172/jci76833
[5] JUAN L. GOMEZ. Chemogenetics revealed: DREADD occupancy and activation via converted clozapine[J]. Science, 2017, 357 6350. DOI:10.1126/science.aan2475
[6] CATHERINE A. MARCINKIEWCZ. Serotonin engages an anxiety and fear-promoting circuit in the extended amygdala[J]. Nature, 2016, 537 7618: 97-101. DOI:10.1038/nature19318 |
| | CLOZAPINE N-OXIDE Preparation Products And Raw materials |
|